In a post-marketing study conducted in 1500 Indian patients, only 9 adverse events were reported in 9 patients (0.63%) that were of mild to moderate intensity.
في دراسة ما بعد التسويق أجريت على 1500 مريض هندي, فقط 9 آثار ضائرة سجلت على 9 مرضى (0.63%) والتي كانت خفيفة لمعتدلة الشدة.